GENFIT Share Price Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 89.63M 96.69M 7.7B | Sales 2025 * | 48.78M 52.62M 4.19B | Capitalization | 168M 182M 14.46B |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.18M 1.29B | Net income 2025 * | -21M -22.65M -1.8B | EV / Sales 2024 * | 1.57 x |
Net cash position 2024 * | 27.6M 29.77M 2.37B | Net cash position 2025 * | 44.9M 48.43M 3.86B | EV / Sales 2025 * | 2.53 x |
P/E ratio 2024 * |
7.2
x | P/E ratio 2025 * |
26
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.71% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 30/04/18 |
Founder | 68 | 31/08/99 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 03/03/21 | |
Founder | 68 | 31/08/99 | |
Founder | 52 | 14/09/99 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |